Pharminent

5 questions: making Multiple Sclerosis care more patient-centric

Trishna Bharadia, Multiple Sclerosis patient advocate, wants to make MS care more patient-centric.
The post 5 questions: making Multiple Sclerosis care more patient-centric appeared first on Pharmaphorum. https://pharmaphorum.com/views-and-analysis/multiple-sclerosis-patient-centric/

Filed under: MS

Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones

EAST HANOVER, N.J., Aug. 21, 2017 /PRNewswire/ — Novartis announced today the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone, without the need for clinic visits. The study, Evaluation of Evidence from Smart Phone Sensors… http://www.prnewswire.com/news-releases/novartis-launches-first-large-scale-research-study-in-multiple-sclerosis-that-allows-participants-to-contribute-from-smartphones-300506716.html

Filed under: MS

Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies

SAN JUAN, Puerto Rico, July 27, 2017 /PRNewswire/ — Abarca Health, a pharmacy benefit management (PBM) and technology company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (NASDAQ: BIIB) for select products in… http://www.prnewswire.com/news-releases/abarca-health-and-biogen-announces-innovative-value-based-contract-for-multiple-sclerosis-therapies-300495565.html

Filed under: MS

Roche’s Ocrevus racks up more positive MS data in relapsing and primary progressive forms

The positive data for Roche’s Ocrevus keep on coming. Friday, the company’s Genentech unit announced that the multiple-sclerosis fighter had significantly cut down disease activity and disability progression in patients with relapsing forms of the disease and those with the harder-to-treat, primary progressive forms. http://www.fiercepharma.com/marketing/roche-s-ocrevus-racks-up-more-positive-ms-data-relapsing-and-primary-progressive-forms

Filed under: MS

Celgene’s Data Could Lead To New Option For Multiple Sclerosis Patients

Celgene reported Monday that an experimental pill for the main type of multiple sclerosis met its main goals in a two-year study. By the end of the year, the Summit, NJ, drugmaker will ask the FDA to consider the drug, ozanimod, for approval. The Celgene (NASDAQ: CELG) drug is being tested in patients with relapsing […] http://www.xconomy.com/new-york/2017/05/22/celgenes-data-could-lead-to-new-option-for-multiple-sclerosis-patients/

Filed under: MS

Novartis real-world data confirms benefit of Gilenya in relapsing MS

https://www.europeanpharmaceuticalreview.com/50978/news/industry-news/novartis-real-world-data/

Filed under: MS

Breakthrough multiple sclerosis research sheds light on cause of the disease

Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of multiple sclerosis.
read more http://www.pharmafile.com/news/513890/breakthrough-multiple-sclerosis-research-sheds-light-cause-disease

Filed under: MS

NICE reverses decision on medication for relapsing multiple sclerosis

The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away from the headlines, the body continues to perform its role of determining which medicines will be available to patients. In this case, it has approved Biogen’s Zinbryta for patients suffering from relapsing remitting multiple sclerosis, though with the caveat of there being particular circumstances dependent for its use.
read more http://www.pharmafile.com/news/513589/nice-reverses-decision-medication-relapsing-multiple-sclerosis

Filed under: MS

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

https://www.thestreet.com/story/14006548/1/celgene-multiple-sclerosis-pill-succeeds-in-first-late-stage-clinical-trial.html

Filed under: MS

FDA extends review of Genentech’s application for multiple sclerosis drug OCREVUS

The US Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) date for review of Genentech’s Biologics License Application (BLA) for OCREVUS (ocrelizumab) to March 28, 2017. http://processandproduction.pharmaceutical-business-review.com/news/fda-extends-bla-review-of-genentechs-ocrevus-211216-5702612

Filed under: MS

Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026

LONDON, Nov. 7, 2016 /PRNewswire/ — Report DetailsMS Drugs – Discover R&D Trends and Markets with Highest Revenue PotentialsWhere is the multiple sclerosis drugs market heading? Visiongain’s new study predicts that pharma industry’s revenues from 2016. There you find potentials for… http://www.prnewswire.com/news-releases/multiple-sclerosis-drugs-market-and-rd-outlook-2016-2026-300358877.html

Filed under: MS

Novartis’ Multiple Sclerosis Life Cycle Looks More Assured

http://seekingalpha.com/article/4007018-novartis-multiple-sclerosis-life-cycle-looks-assured

Filed under: MS

Roche’s Ocrevus more effective than Merck’s Rebif, company claims

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The data will be presented during the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) this week in London.
read more http://www.pharmafile.com/news/508007/roche-s-ocrevus-more-effective-merck-s-rebif-company-claims

Filed under: MS

Novartis’ BAF312 meets main goal in secondary progressive multiple sclerosis trial

A phase III study, assessing the efficacy and safety of Novartis’ BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, versus placebo. http://clinicaltrials.pharmaceutical-business-review.com/news/novartis-baf312-meets-main-goal-in-secondary-progressive-multiple-sclerosis-trial-250816-4988439

Filed under: MS

Analysts: Payers moving to address MS market as prices rise

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts. http://www.mmm-online.com/analysts-payers-moving-to-address-ms-market-as-prices-rise/article/515426/

Filed under: MS

An Antibody-Based Drug for Multiple Sclerosis

NewsResearchers have developed an antibody with potential therapeutic effects against multiple sclerosis. http://www.dddmag.com/news/2016/07/antibody-based-drug-multiple-sclerosis

Filed under: MS

Multiple Sclerosis Pipeline Review Report of 178 Companies

PUNE, India, July 14, 2016 /PRNewswire/ —
ReportsnReports.com adds “Multiple Sclerosis – Pipeline Review, H1 2016" market research report to its store providing an overview of the Multiple Sclerosis’s therapeutic pipeline complete with comparative analysis at various stages,… http://www.prnewswire.com/news-releases/multiple-sclerosis-pipeline-review-report-of-178-companies-586776231.html

Filed under: MS

EMA and FDA accept for review Roche’s Ocrevus for two forms of multiple sclerosis

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted to review Roche’s marketing applications for Ocrevus (ocrelizumab) to treat two forms of multiple sclerosis. http://processandproduction.pharmaceutical-business-review.com/news/ema-and-fda-accept-for-review-roches-ocrevus-for-two-forms-of-multiple-sclerosis-290616-4936065

Filed under: MS

Roche anticipates quicker U.S. approval for new MS drug

ZURICH (Reuters) – Roche’s new multiple sclerosis (MS) drug could be approved in the United States this year, earlier than previously forecast, the Swiss drugmaker said on Tuesday, after winning the U.S. regulator’s priority review status for the medicine. http://www.reuters.com/article/us-roche-ms-drug-idUSKCN0ZE0AQ

Filed under: MS

Flex Pharma starts phase 2 efficacy study in multiple sclerosis

Flex Pharma has initiated a Phase 2 efficacy study in multiple sclerosis (MS) patients in Australia. http://clinicaltrials.pharmaceutical-business-review.com/news/flex-pharma-starts-phase-2-efficacy-study-in-multiple-sclerosis-160616-4925052

Filed under: MS

Categories